The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SONN | +71.58% | -99.92% | -75.98% | -100% |
| S&P | +12.28% | +84.74% | +13.06% | +162% |
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded in 2011 and is headquartered in Princeton, NJ.
No news articles found for Sonnet BioTherapeutics.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | -5.3% |
| Gross Margin | 97.78% | 105.0% |
| Market Cap | $3.93M | 34.5% |
| Market Cap / Employee | $0.30M | 0.0% |
| Employees | 13 | 0.0% |
| Net Income | -$3.78M | -7.7% |
| EBITDA | -$3.78M | -7.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.32M | -91.0% |
| Accounts Receivable | $0.50M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.07M | -15.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -345.29% | -244.4% |
| Return On Invested Capital | 4382.37% | 368.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.76M | 42.7% |
| Operating Free Cash Flow | -$1.76M | 42.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -8.96 | -1.95 | 1.00 | 5.85 | 512.18% |
| Price to Sales | 233.57 | 2.95 | 5.25 | 4.92 | -94.18% |
| Price to Tangible Book Value | 1.67 | -1.95 | 1.00 | 5.85 | 512.18% |
| Enterprise Value to EBITDA | -1.37 | 0.64 | -0.78 | -1.23 | 227.90% |
| Return on Equity | -200.1% | -264.6% | -285.3% | -715.0% | - |
| Total Debt | $0.13M | $0.11M | $0.09M | $0.07M | -54.17% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
